DVADaVita

$180.08
DaVita logo

Price

$180.08+41%1Y
1M-23%1Y+41%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average
8/10
Value55
Quality78
Momentum69
Growth48
Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for more than 25 years. We care for patients at every stage and setting along their kidney health journey–from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and in skilled nursing facilities.

In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR

P/E (TTM)14.8
Market Cap$13.34B
1Y Return+41%
5Y Return+50%

Business segments

Q2 2026 · $3.60B

The company’s own SEC segment disclosure.

  • U.S.Dialysis With Intersegment$2.99B83%
  • Other Operating Segments With Intersegment$372.4M10%
  • All Other$236.4M7%

DaVita (DVA) reported revenue of $3.55B in Q2 2026 (quarter ended June 30, 2026), up 5.2% from the same quarter a year earlier. That came with net income of $265M (7.5% of revenue). For the full year FY2025, revenue was $13.6B (+6.5% year on year) and net income $747M. Its largest segment in 2026-Q2 was U.S.Dialysis With Intersegment at $2.99B, 83% of the disclosed total, just ahead of Other Operating Segments With Intersegment at 10%.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.